目的 探討康萊特注射液聯(lián)合貝伐珠單抗治療晚期非小細(xì)胞肺癌的療效。方法 選取2020年10月-2023年6月河北省中醫(yī)院收治的晚期非小細(xì)胞肺癌患者86例,采用隨機(jī)數(shù)表法分為對(duì)照組(43例)和治療組(43例)。對(duì)照組患者靜脈滴注貝伐珠單抗注射液,首次化療后給藥,劑量15 mg/kg,1次/3周,每次間隔3~5 d再給藥,共治療3次。治療組在對(duì)照組基礎(chǔ)上靜脈滴注康萊特注射液,200 mL/次,1次/d,連續(xù)滴注21 d,21 d為1個(gè)周期,1個(gè)周期結(jié)束后間隔3~5 d進(jìn)入下1個(gè)周期,共治療3個(gè)周期。觀察兩組患者臨床療效,比較治療前后兩組患者血清腫瘤標(biāo)記物癌胚抗原、細(xì)胞角質(zhì)蛋白19片段抗原21-1(CYFRA21-1)和糖類抗原125水平,免疫功能指標(biāo)CD8⁺、CD3⁺、CD4⁺和CD4⁺/CD8⁺水平及不良反應(yīng)情況。結(jié)果 治療后,治療組疾病控制率為88.37%,高于對(duì)照組的69.77%(P<0.05)。治療后,兩組患者癌胚抗原、CYFRA21-1、糖類抗原125水平、CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明顯降低(P<0.05),且治療組這些指標(biāo)水平明顯低于對(duì)照組(P<0.05)。治療期間,治療組不良反應(yīng)率為51.16%,明顯低于對(duì)照組72.09%(P<0.05)。結(jié)論 康萊特注射液聯(lián)合貝伐珠單抗治療晚期非小細(xì)胞肺癌具有較高的疾病控制率,并可改善腫瘤標(biāo)志物水平,減輕化療的不良反應(yīng)及其對(duì)免疫功能的不利影響。

Objective To investigate the efficacy of Kanglaite Injection combined with bevacizumab in treatment of advanced non-small cell lung cancer. Methods Patients (86 cases) with advanced advanced non-small cell lung cancer in Hebei Provincial Hospital of Traditional Chinese Medicine from October 2020 to June 2023 were divided into control (43 cases) and treatment (43 cases) group according to random number table method. Patients in the control group were iv administered with Bevacizumab Injection, the dose was 15 mg/kg after the first chemotherapy, once every 3 weeks, each time at an interval of 3 to 5 days, they were treated for 3 times. Patients in the treatment group were iv administered with Kanglaite Injection on the basis of the control group, 200 mL/time, once daily for 21 d, after 21 d the interval was 3-5 d to enter the next 21 d, they were treated for 3 cycles. After treatment, the clinical evaluations were evaluated, the levels of tumor markers carcinoembryonic antigen, CYFRA21-1 and CA125, the levels of immune function indicators CD8⁺, CD3⁺, CD4⁺ and CD4⁺/CD8⁺, adverse reactions in two groups before and after treatment were compared. Results After treatment, the disease control rate in the treatment group was 88.37%, which was higher than that in the control group (69.77%, P < 0.05). After treatment, the levels of carcinoembryonic antigen, CYFRA21-1, carbohydrate antigen 125, CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly decreased, and the level of these indexes in the treatment group was significantly lower than that in the control group (P < 0.05). During the treatment, the adverse reaction rate in the treatment group was 51.16%, which was significantly lower than that in the control group (72.09%, P < 0.05). Conclusion The combination of Kanglaite Injection and bevacizumab in treatment of advanced non-small cell lung cancer has a high disease control rate, can also improve the level of tumor markers and reduce the adverse reactions of chemotherapy and its adverse effects on immune function.

R979.1

河北省中醫(yī)藥管理局科研計(jì)劃項(xiàng)目（2020004）